Clinical Research
XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Th...
September 24, 2026 | News
Caliway’s CBL-514 Hits Phase II Pain-Reduction Endpoint in Dercum’s Disease
Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations...
September 23, 2026 | News
NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-s...
September 23, 2026 | News
Bestzyme Completes World’s First Automated Smart Production Line for Sweet Proteins
Bestzyme, a synthetic biology company under GenScript Biotech, announced the completion of the world's first dedicated, automated smart production li...
September 23, 2026 | News
IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer
MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...
September 21, 2026 | News
Daiichi Sankyo, AstraZeneca’s Enhertu Wins EU Panel Backing for Early Breast Cancer
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vers...
September 21, 2026 | News
Single Cell Discoveries Acquires TATAA Biocenter to Build Integrated Discovery-to-Validation CRO
Single Cell Discoveries (SCD), a specialist contract research organization (CRO) focused on discovery transcriptomics, has completed the acquisition of TAT...
September 16, 2026 | News
US FDA Approves Telix’s Pixclara as First FET-PET Imaging Drug for Brain Cancer
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians ...
September 15, 2026 | News
Accro Bioscience’s AC-101 Enters China’s Rare Disease Innovative Drug Pilot Programme for Blau Syndrome
Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring...
September 15, 2026 | News
Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201
Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") announced that they have signed a research collaboration and license agr...
September 14, 2026 | News
AstraZeneca Secures US FDA Approval for ETCAMAH Combination in Advanced Breast Cancer
Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an e...
September 08, 2026 | News
Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
September 04, 2026 | News
IDT and Ansa Expand Global Access to Complex DNA Synthesis Through Integrated Ordering
Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options Global adoption growing with more than 400...
September 03, 2026 | News
Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis
Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...
September 03, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
